Utility of BRAF VE1 Immunohistochemistry as a Screening Tool for Colorectal Cancer Harboring BRAF V600E Mutation.

about

Utility of BRAF VE1 Immunohistochemistry as a Screening Tool for Colorectal Cancer Harboring BRAF V600E Mutation.

Item

http://www.wikidata.org/entity/Q55015727

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Utility of BRAF VE1 Immunohist ...... Harboring BRAF V600E Mutation.

@en

Utility of BRAF VE1 Immunohist ...... Harboring BRAF V600E Mutation.

@nl

type

Item

label

Utility of BRAF VE1 Immunohist ...... Harboring BRAF V600E Mutation.

@en

Utility of BRAF VE1 Immunohist ...... Harboring BRAF V600E Mutation.

@nl

prefLabel

Utility of BRAF VE1 Immunohist ...... Harboring BRAF V600E Mutation.

@en

Utility of BRAF VE1 Immunohist ...... Harboring BRAF V600E Mutation.

@nl

P1476

Utility of BRAF VE1 Immunohist ...... Harboring BRAF V600E Mutation.

@en

P2093

Byung-Kwan Jeong

http://www.w3.org/2001/XMLSchema#string

Chang Sik Yu

http://www.w3.org/2001/XMLSchema#string

Jeong-Hwa Kwon

http://www.w3.org/2001/XMLSchema#string

Jihun Kim

http://www.w3.org/2001/XMLSchema#string

Yong Sik Yoon

http://www.w3.org/2001/XMLSchema#string

P2860

BRAF Mutation in Colorectal Cancer: An Update

Feasibility of multiplexed gene mutation detection in plasma samples of colorectal cancer patients by mass spectrometric genotyping.

BRAF V600E immunohistochemistry is reliable in primary and metastatic colorectal carcinoma regardless of treatment status and shows high intratumoral homogeneity

The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis.

BRAF V600E mutation-specific antibody: A review.

Performance comparison of three BRAF V600E detection methods in malignant melanoma and colorectal cancer specimens.

A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens.

VE1 immunohistochemistry predicts BRAF V600E mutation status and clinical outcome in colorectal cancer

Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication

CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer.

P304

157-163

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4132/JPTM.2018.03.28

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-03-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29590746

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

immunohistochemistry

P932

5964290

http://www.w3.org/2001/XMLSchema#string